Femasys Inc. (FEMY)
NASDAQ (CM) NASDAQ (CM) Primary 
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.
Femasys is a commercial-stage medtech company targeting OB/GYNs with in-office fertility and permanent birth control solutions. FEMY's $30M PIPE recapitalization ties full funding to commercial traction; current market cap is below cash, creating a deep value setup. The investment thesis hinges on commercial execution: a lean, focused sales force converting OB/GYNs and health systems to the Fertility FastTrack suite.
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.21 per share a year ago.
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.19 per share a year ago.
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago.
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI
FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.
